Biotechnology - Neurological, Oncology


Current filters:


Popular Filters

Eisai's R&D unit Kan Research Institute starts full-scale operation at new facility


Japanese drug major Eisai Co says that its R&D subsidiary KAN Research Institute held a dedication ceremony…

BiotechnologyEisaiImmunologicalsJapanKan Research InstituteNeurologicalOncologyResearch

Germany’s Merck invests in further research partnerships in Israel

Germany’s Merck invests in further research partnerships in Israel


German pharma and chemicals firm Merck KGaA says it is increasingly counting on partnerships with Israeli…

BiotechnologyChanBioFinancialMerck KGaAMetabomedNeurologicalOncologyResearchRest of the World

Ablynx and Merck Serono expand collaboration on Nanobodies

Ablynx and Merck Serono expand collaboration on Nanobodies


Ablynx and Merck Serono have expanded their collaboration on the co-discovery and co-development of Nanobodies.

AblynxBiotechnologyEuropeImmunologicalsMerck SeronoNeurologicalOncologyResearch

Acetylon snags $100 million upfront cash and acquisition option


Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

US FDA backs news indications for Latuda; grants Priority Review for Perjeta


Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Celgene partners with FORMA Thera on drugs targeting protein homeostasis


Privately-held FORMA Therapeutics has entered into a strategic collaboration agreement with US biotech…

BiotechnologyCelgeneFORMA TherapeuticsLicensingNeurologicalOncologyResearch

Teva pulls out of CureTech deal; AC Immune drops CI-91


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that it has terminated its collaboration…

AC ImmuneBiotechnologyCT-011CureTechLicensingNeurologicalOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Positive recommendations from EMA's CHMP for Selincro, Adasuve and Perjeta


Last week's deliberations of the European Medicines Agency's Committee for Medicinal Products for Human…

AdasuveAlexza PharmaceuticalBiotechnologyEuropeFerrer InternacionalLundbeckNeurologicalOncologyPerjetaPharmaceuticalRegulationRocheSelincro

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine


US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

FDA OKs new indication for Janssen's Nucynta and fast tracks Zytiga sNDA


There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries…

BiotechnologyJanssenJohnson & JohnsonNeurologicalNorth AmericaNucyntaOncologyPharmaceuticalRegulationZytiga

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra


The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Japanese approval for Regnite and Ranmark


Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Back to top